Eli Lilly's Weight-Loss Drug Demand Is Nearly Limitless. Here's What Comes Next for the $1 Trillion Drugmaker24/7 Wall Street • 08/05/26
LLY Q2 Earnings Top, GLP-1 Drugs Fuel Growth, Sales Guidance RaisedZacks Investment Research • 08/05/26
Stock Market Midday, Aug. 5: Eli Lilly Pops and AMD Drops in Mixed Morning MarketsThe Motley Fool • 08/05/26
Eli Lilly Q2 Earnings Review: Breath-Taking Results Mean Higher Ceiling On Stock Price TargetSeeking Alpha • 08/05/26
Lilly (LLY) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 08/05/26
Eli Lilly's Diabetes And Obesity Drugs Blow Past Expectations; Shares PopInvestors Business Daily • 08/05/26
Eli Lilly raises annual revenue forecast as obesity, diabetes drug demand stay strongReuters • 08/05/26
Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surgeCNBC • 08/05/26
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progressPRNewsWire • 08/05/26
Novo Nordisk Stock Stumbles On A Key Miss As Its Battle With Eli Lilly Heats UpInvestors Business Daily • 08/04/26
Eli Lilly Is Up 7% in 2026 and Has Major Catalysts on the Way. Is the Rally Just Getting Started?The Motley Fool • 08/04/26